Clinical trials: Placebo Response
Allergic Rhinitis
Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
The purpose of this study is to determine the safety and effect of CAL-263 in subjects with allergic rhinitis.
- Trial name
- NCT01066611
- Testing
- CAL-263
- Where
- Austria
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Septic Shock
Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial
Sepsis-associated encephalopathy is associated with high mortality rates and long-term neuropsychiatric disorders. Currently, there is no specific treatment for sepsis-associated encephalopathy.
- Trial name
- KiSS (NCT06851078)
- Testing
- Levetiracetam IV
- Volunteers
- 280 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Septic Shock, Cardiac Output
Milrinone Versus Placebo in Patients With Septic Shock
Sepsis is one of the most serious healthcare problems, worldwide, and financial burdens. The overall mortality of severe sepsis/septic shock was 44.5-52.6%. A common cause of death is refractory shock and multi-organ failure.
- Trial name
- NCT05122884
- Testing
- Milrinone
- Where
- 2 sites in Thailand
- Volunteers
- 64 people
- Sponsor
- Mahidol University
Osteoarthritis of the Knee
Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis
The objective of this study was to explore the efficacy, dose-response and safety of PG201 tablet in Korean patients with osteoarthritis.
- Trial name
- NCT01122485
- Testing
- PG201
- Sponsor
- Helixmith Co., Ltd.
Pneumonia, Diarrhea
Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease
Title: Impact of daily zinc supplementation to infants born with low birth weight on mortality and severe disease requiring hospitalization Background: Zinc supplementation was shown to prevent diarrhea and pneumonia in 6 month…
- Conditions
- Pneumonia, Diarrhea, Meningitis, Sepsis
- Trial name
- NCT00495690
- Testing
- Oral zinc gluconate (5 mg elemental)
- Where
- India
- Volunteers
- 2,012 people
- Sponsor
- Society for Applied Studies
Endotoxemia, Systemic Inflammatory Response
PK/PD of EA-230 During Endotoxemia
EA-230 is a newly developed synthetic compound with anti-inflammatory properties. Pre-clinical data indicate that EA-230 may be a valuable treatment for systemic inflammation resulting from a variety of causes such as surgery…
- Trial name
- NCT02629874
- Testing
- EA-230, Endotoxin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Analgesia
Breath Metabolomics of Placebo Effects, a Pilot Study
This study is to analyze the breath metabolome before and after the administration of a placebo in an established experimental pain procedure in healthy subjects in order to investigate placebo effects, and whether they induce…
- Trial name
- BMPE (NCT04956718)
- Testing
- Cold Pressor Test (CPT)
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital Basel
Dengue, Dengue With Warning Signs
Anakinra in Dengue With Hyperinflammation ( AnaDen )
This study aims to evaluate the effect of anakinra in dengue patients with hyperinflammation as compared to placebo Primary Objective: To evaluate the efficacy of Anakinra in moderate-severe dengue patients with…
- Conditions
- Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra
- Trial name
- NCT05611710
- Testing
- Anakinra
- Where
- Vietnam
- Volunteers
- 160 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Hypercholesterolemia
A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
A study to evaluate the cholesterol-lowering effects of ezetimibe in participants with primary hypercholesterolemia (high cholesterol) after eating a meal that is high in cholesterol.
- Trial name
- NCT00101439
- Testing
- ezetimibe
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Post Traumatic Stress Disorder, Traumatic Brain Injury
Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI
This will be a randomized placebo controlled study to test the efficacy of cannabidiol (CBD) as a treatment for symptoms of post-traumatic stress disorder (PTSD).
- Trial name
- NCT04550377
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- NYU Langone Health
Vaccine Response Impaired, Immune Suppression
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1…
- Conditions
- Vaccine Response Impaired, Immune Suppression, Covid19
- Trial name
- NCT04885907
- Testing
- mRNA-1273 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Postoperative Pain
An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing elective arthroscopic shoulder surgery on the basis of pharmacokinetics, efficacy and safety evaluations.
- Trial name
- NCT00993798
- Testing
- SABER-Bupivacaine Treatment 1a, Bupivacaine HCl Treatment 1c, SABER-Bupivacaine Treatment 2a
- Where
- 10 sites in Austria, Germany and 3 more
- Volunteers
- 107 people
- Sponsor
- Durect
Smartphone Application, Placebo Effect
Smartphone Application, Mood and Stress
The purpose of this study is to investigate the placebo effect in a smartphone-based training, ostensibly designed to improve mood and perceived stress by daily exposition to either mock sound or color.
- Conditions
- Smartphone Application, Placebo Effect, Mood, Stress
- Trial name
- NCT02365220
- Testing
- No expectancy (control), Prospective expectancy, Retrospective expectancy
- Where
- Switzerland
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
To perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live…
- Trial name
- CAIVT (NCT00192322)
- Testing
- CAIV-T 10^7, CAIVT 10^5, TIV
- Where
- 2 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Insomnia Disorder
Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
- Trial name
- NCT02839200
- Testing
- ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg
- Where
- 35 sites in United States, Germany and 4 more
- Volunteers
- 360 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Central Line-Associated Bloodstream Infection
Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Use of long-term central venous access devices (including tunneled lines and ports) can be associated with development of bloodstream infection caused by build-up of bacteria or fungus on the inside of the device, called central…
- Trial name
- NCT01472965
- Testing
- ethanol
- Where
- 2 sites in United States, Australia
- Volunteers
- 95 people
- Sponsor
- St. Jude Children's Research Hospital
Healthy, Placebo Effect
Experimental Pain Reporting Accuracy and Placebo Response
Good clinical care relies on precise evaluation of patients' conditions. Chronic pain and other neurological and psychiatric diagnoses pose challenges because their assessment depends on subjective patient-reported outcome…
- Conditions
- Healthy, Placebo Effect, Pain
- Trial name
- NCT03950999
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Haifa
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Fibromyalgia
Impact of Susceptibility to Placebo on the Effect of Transcranial Direct Current Stimulation (tDCS) in Fibromyalgia
Fibromyalgia (FM) is a syndrome characterized by generalized musculoskeletal pain, fatigue, non-restorative sleep, cognitive changes, depressive and neurovegetative symptoms.
- Trial name
- FIBROTEC (NCT05845528)
- Testing
- s-tDCS, a- tDCS
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.